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Abstract
Aim: To investigate whether type 2 diabetes susceptibility genes and body weight influence the development of islet
autoantibodies and the rate of progression to type 1 diabetes.
Methods: Genotyping for single nucleotide polymorphisms (SNP) of the type 2 diabetes susceptibility genes CDKAL1,
CDKN2A/2B, FTO, HHEX-IDE, HMGA2, IGF2BP2, KCNJ11, KCNQ1, MTNR1B, PPARG, SLC30A8 and TCF7L2 was obtained in 1350
children from parents with type 1 diabetes participating in the BABYDIAB study. Children were prospectively followed from
birth for islet autoantibodies and type 1 diabetes. Data on weight and height were obtained at 9 months, 2, 5, 8, 11, and 14
years of age.
Results: None of type 2 diabetes risk alleles at the CDKAL1, CDKN2A/2B, FTO, HHEX-IDE, HMGA2, IGF2BP2, KCNJ11, KCNQ1,
MTNR1B, PPARG and SLC30A8 loci were associated with the development of islet autoantibodies or diabetes. The type 2
diabetes susceptible genotype of TCF7L2 was associated with a lower risk of islet autoantibodies (7% vs. 12% by age of 10
years, P=0.015, Pcorrected=0.18). Overweight children at seroconversion did not progress to diabetes faster than non-
overweight children (HR: 1.08; 95% CI: 0.48–2.45, P.0.05).
Conclusions: These findings do not support an association of type 2 diabetes risk factors with islet autoimmunity or
acceleration of diabetes in children with a family history of type 1 diabetes.
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Introduction
Type 1A diabetes and type 2 diabetes are etiologically different
forms of insulin deficiency [1]. Type 1 diabetes is a chronic
autoimmune disease in which selective destruction of the
pancreatic islet beta cells leads to a marked insulin deficit [2].
Autoimmunity is evidenced by autoantibodies against specific islet
proteins and can precede disease by many years [2]. Type 2
diabetes is characterized by insulin resistance and impaired islet
beta cell function which together result in a net inability to supply
sufficient insulin to meet the body’s demands and eventual beta
cell loss [1]. Genetic susceptibility is mostly non-overlapping in the
two forms of diabetes mellitus, but several studies have suggested
that there could be contribution of risk factors from type 2 diabetes
to the pathogenesis of type 1 diabetes and vice versa, leading to the
concept of double diabetes [3,4]. In particular, increasing
population weight and body mass index (BMI) has been linked
to increasing type 1 diabetes trends [3,4,5,6]. Our previous studies
in children who are offspring of patients with type 1 diabetes found
no association of body weight or insulin resistance with islet
autoimmunity [7]. Here, as an extension of these studies we
examine associations of type 2 diabetes susceptibility genotypes on
the development of autoimmunity against islet beta cells and
examine the effect of these genotypes and body weight on
progression to diabetes after islet autoantibody seroconversion.
The findings suggest that type 2 diabetes risk factors are not a
common feature of type 1 diabetes occurring in first degree
relatives of patients with type 1 diabetes and do not support a
significant role of these type 2 diabetes associated factors in the
pathogenesis of childhood diabetes in families affected with type 1
diabetes.
Materials and Methods
The study was performed in children from the BABYDIAB
study, a longitudinal study examining the natural history of islet
autoimmunity and type 1 diabetes in 1650 children born to a
mother with type 1 diabetes or a father with type 1 diabetes [8].
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(GADA), insulinoma antigen 2 (IA-2A) and zinc transporter 8
(ZnT8-A) were measured in samples taken at all scheduled visits (at
9 months, 2, 5, 8, 11, 14, 17 and 20 years of age), and every 6
months in children with islet autoantibodies. The median follow-
up time from birth to last sample was 11.1 years (range 0.75–21.7
years), and the median follow-up from islet autoantibody
seroconversion to last sample was 5.4 years (range 0.1–19.6 years).
Families were asked to report occurrence of symptoms of diabetes.
In children with islet autoantibodies, a yearly oral glucose
tolerance test was performed. Diabetes onset was defined
according to ADA criteria which include unequivocal hypergly-
cemia with acute metabolic decompensation, or the observation
on at least two occasions of a 2-hour plasma glucose .200 mg/dL
after an oral glucose challenge, or a random blood glucose
.200 mg/dL if accompanied by unequivocal symptoms. Since
1997, fasting blood glucose .126 mg/dL on two occasions was
added to the diabetes diagnosis criteria. The BABYDIAB study
was approved by the ethical committee of Bavaria, Germany
(No. 95357). All families gave written informed consent to
participate in the study. Investigations were carried out in
accordance with the principles of the Declaration of Helsinki, as
revised in 2000.
IAA, GADA, IA-2A, and ZnT8A were determined centrally by
the Institute of Diabetes Research Munich using radiobinding
assays as previously described [8,9]. The upper limit of normal for
each assay was determined using Q–Q plots and corresponded to
the 99
th percentile of control children. Offspring were considered
islet autoantibody-positive when two consecutive samples collected
after birth were positive. Islet autoantibody assays were evaluated
by the Diabetes Autoantibody Standardization Program (DASP;
laboratory 121) [10,11,12]. Sensitivity and specificity in the 2009
DASP workshop were 70% and 98% for IAA, 86% and 93% for
GADA, 72% and 100% for IA-2A, 51% and 100% for the ZnT8A
tryptophan variant, and 68% and 100% for the ZnT8A arginine
variant, respectively.
Genotyping of the CDKAL1 rs4712526, CDKN2A/2B
rs10811661, FTO rs8050136, HHEX-IDE rs5015480, HMGA2
rs1122590, IGF2BP2 rs4402960, KCNJ11 rs5215, KCNQ1
rs2237892, MTNR1B rs1387153, PPARG rs1801282, SLC30A8
rs3802177 and TCF7L2 rs7901695 SNPs was performed with the
MassARRAY system using the iPLEX
TM chemistry (Sequenom,
San Diego, CA, USA) as previously described [13]. The 12 loci
included 9 originally reported by [14] plus 3 that were used for
genotyping of the KORA study cohort [15]. To control for
reproducibility, 16.3% of samples were genotyped in duplicate
with discordance rate ,0.5%. All SNPs were tested for deviation
from Hardy-Weinberg equilibrium by means of chi-square or
Fisher’s exact test. DNA samples for genotyping were available
from 1350 children. HLA-DRB1, HLA-DQA1 and HLA-DQB1
alleles were typed using PCR-amplified DNA and non-radioactive
sequence-specific oligonucleotide probes as described previously
[16]. Classification into high risk HLA genotypes was based on
TEDDY study inclusion genotypes for first degree relatives as
previously described [17].
Data on weight and height during follow-up at age 9 months, 2,
5, 8, 11, and 14 years of age were collected from paediatric records
which were completed by trained staff at birth and by
paediatricians at visits after birth. For analysis, data on height,
weight and BMI at follow-up were adjusted for gender and exact
age at examination and were expressed as percentiles using
German reference data [18]. Low weight was defined as BMI
percentile #10, normal weight was defined as BMI percentile
between 10 and 90, overweight was defined as BMI percentile
$90.
The probability of islet autoantibodies was estimated by
Kaplan-Meier analysis. Hazards ratios (HRs) were determined
using Cox’s proportional hazards model. Within islet autoantibody
positive children, Kaplan-Meier analysis was used to calculate the
probability of progression to diabetes where follow-up time was
calculated from the age when autoantibodies were first detected to
the age of type 1 diabetes diagnosis, or last contact. Based on a
corrected alpha value of 0.004 and a desired statistical power of
0.8, our data allowed us to detect HRs for the probability of islet
autoantibodies of #0.77 or $1.34 for TCF7L2 and of #0.38 or
$5.25 for PPARG. For all other genes, the upper and lower limits
of the respective detectable HRs were between these ranges.
Differences of weight, height and BMI between children who
developed islet autoantibodies and children who were islet
autoantibody negative during follow-up at age 9 months, 2, 5, 8,
11, and 14 years were compared using Mann-Whitney-U Test.
For comparison of BMI, weight, and hight at the age of
seroconversion, a nested case–control population was selected
from the 1650 offspring participating in BABYDIAB. These
included 141 islet autoantibody positive children (cases) with
weight, and height data at the age of islet autoantibody
seroconversion. For each case, two controls were selected from
the islet autoantibody negative children matching for gender and
data of birth. In the control children, weight and height was
obtained at the age corresponding to the age of seroconversion of
the respective case. Seven of these control children did not have
complete weight and height data resulting in a total of 275
controls. The distribution of BMI, weight, and height were
compared using Chi-Square Test.
The statistical analysis was performed using the Statistical
Package for the Social Sciences (SPSS 19.0; SPSS Inc., Chicago,
IL, USA).
Results
Influence of the type 2 diabetes susceptibility genes on
islet autoimmunity and diabetes
At the time of the analysis 152 BABYDIAB children developed
islet autoantibodies. None of type 2 diabetes risk alleles at the
CDKAL1, CDKN2A/2B, FTO, HHEX-IDE, HMGA2, IGF2BP2,
KCNJ11, KCNQ1, MTNR1B, PPARG and SLC30A8 loci were
associated with the development of islet autoantibodies in our
cohort (Table S1). The type 2 diabetes C allele of TCF7L2
(rs7901695) was associated with a lower risk of islet autoimmunity
compared to the TT genotype (HR: 0.66; 95% CI: 0.47–0.94;
P=0.022), but significance was lost after correcting for multiple
comparisons (Pcorrected=0.264). The cumulative risk of developing
islet autoantibodies by age 10 years was 7% (95% CI: 5–9%) in
children carrying the TCF7L2 CT or TCF7L2 CC genotype
compared to 12% (95% CI: 10–14%) in children carrying the type
2 diabetes protective TCF7L2 TT genotype (P=0.015; Pcorrected=
0.18) (Figure 1). The observed lower risk was unaffected by
adjustment for HLA risk genotype (HR: 0.63; 95% CI: 0.44–0.89;
P=0.009; Pcorrected=0.108). 21% of the cohort had high risk HLA
genotypes. When selecting for this high risk population, the
cumulative risk of developing islet autoantibodies by age 10 years
was not different between children carrying the TCF7L2 CT or
TCF7L2 CC genotype (17%; 95% CI: 11–23%) and children
carrying the type 2 diabetes protective TCF7L2 TT genotype
(22%, 95% CI: 14–30%); (P=0.321); HR 1.23, 95%CI: 0.75–2.2
(P=0.360).
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diabetes (median, 4.08 years after their first islet-positive sample).
None of the type 2 diabetes susceptibility genotypes at the
TCF7L2, CDKAL1, CDKN2A/2B, FTO, HHEX-IDE, HMGA2,
IGF2BP2, KCNJ11, KCNQ1, MTNR1B, PPARG and SLC30A8 loci
were associated with progression to type 1 diabetes (data not
shown).
Weight, Height and BMI at islet autoantibody
seroconverion and in relation to diabetes progression
At the time of islet autoantibody seroconversion 16 antibody
positive children (11.3%) were overweight ($90 BMI percentile),
and 13 (9.2%) were underweight (#10 BMI percentile). The
distribution was similar to the 275 matched islet autoantibody
negative children (12.9% overweight, 9.5% underweight). No
difference between weight, height and BMI was found during
follow-up between children who developed islet autoantibodies
and children who were islet autoantibody negative (Figure 2).
The islet autoantibody children who were overweight did not
progress to diabetes faster than the remaining children (HR: 1.08;
95% CI: 0.48–2.45, P.0.05; Figure S1). Likewise, no difference in
the rate of progression was observed when children were
categorized into tertiles of BMI, weight, or height at islet
autoantibody seroconversion (Figure 3).
Discussion
This study examined the contribution of type 2 diabetes
associated risk factors to the development of islet autoimmunity
and type 1 diabetes in first degree relatives of patients with type 1
diabetes. Consistent with the lack of association of type 2 diabetes
Figure 2. BMI, weight and height between islet autoantibody
positive and negative children. Comparison of BMI (A), BMI percentile
(B), weight percentile (C) and height percentile (D) between islet
autoantibody positive children (dashed line) and islet autoantibody negative
children (solid line) during follow-up at age 9 months, 2, 5, 8, 11, and 14
years. Values are expressed as mean 6 SEM. Numbers below the x-axis
indicate the number of children with available data at the respective age.
doi:10.1371/journal.pone.0035410.g002
Figure 1. Cumulative risk for the development of autoantibod-
ies by the TCF7L2 genotypes. Children are grouped with respect to
TCF7L2 SNP rs7901695 genotype into those carrying TT genotype (solid
line) and the CT or CC genotype (dashed line). Follow-up (x-axis) is from
birth. Numbers below the x-axis indicate the number of autoantibody
negative children remaining on follow-up with respect to age.
doi:10.1371/journal.pone.0035410.g001
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2 diabetes susceptible genotypes did not have an increased risk of
developing islet autoantibodies and these genotypes did not
increase the rate of progression to type 1 diabetes in islet
autoantibody positive children. Indeed, the type 2 diabetes risk
genotypes of TCF7L2 rather decreased the likelihood of develop-
ing islet autoantibodies, but not in children with a high risk HLA
genotype.
A number of the type 2 diabetes susceptibility genes are
associated with increased growth rate and weight [21,22,23,24].
Thus, despite substantial discussion on a link between increasing
weight trends and increased type 1 diabetes development [5,6], the
genetic data which is based on a limited set of known susceptibility
gene regions and a cohort of restricted sample size, neither support
the concept of common pathogenetic mechanisms of type 1
diabetes and type 2 diabetes, nor an increase in type 1 diabetes risk
in the presence of type 2 diabetes risk factors. Consistent with this,
our study found that obesity was infrequent in German first degree
relatives who developed islet autoantibodies. Moreover, although
our study had a limited opportunity to determine whether obesity
increased the rate of progression to diabetes in these children,
weight, height and BMI had no influence on the development of
type 1 diabetes in islet autoantibody positive children.
Overall, the findings indicate that mechanisms involved in type
2 diabetes pathogenesis are unlikely to have important contribu-
tions to the development of autoimmune diabetes in children from
affected families. These findings may not pertain to type 1 diabetes
in older subjects, as well as diabetes in people from unaffected
families.
Supporting Information
Figure S1 Cumulative risk for the progression from
islet autoantibody seroconversion to type 1 diabetes.
Cumulative risk is shown for BMI percentile in children at the
time of islet autoantibody seroconversion. Children are divided
into 3 groups: $90
th percentile (solid line), between 10
th and 90
th
percentile (dotted line) and #10
th percentile (dashed line). Follow-
up (x-axis) is from the age of islet autoantibody seroconverison.
Numbers below the x-axis indicate the number of diabetes-free
children remaining on follow-up.
(TIFF)
Table S1 Gene associations with development of islet
autoimmunity in the BABYDIAB cohort.
(DOC)
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